Cours RegeneRx Biopharmaceuticals, Inc. Other OTC
Actions
RGRX
US75886X1081
Produits pharmaceutiques
CA 2021 | 76,76 k 69,93 k | CA 2022 | 76,76 k 69,93 k | Capitalisation | 19,94 M 18,16 M |
---|---|---|---|---|---|
Résultat net 2021 | -1 M -911 k | Résultat net 2022 | -1 M -911 k | VE / CA 2021 | 298 x |
Trésorerie nette 2021 | 66,69 k 60,76 k | Dette nette 2022 | 1,16 M 1,05 M | VE / CA 2022 | 275 x |
PER 2021 |
-13,9
x | PER 2022 |
-11,5
x | Employés | - |
Rendement 2021 * |
-
| Rendement 2022 |
-
| Flottant | 55,86% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Founder | 86 | 13/05/82 | |
J. Finkelstein
CEO | Chief Executive Officer | 72 | 01/01/84 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
J. Finkelstein
CEO | Chief Executive Officer | 72 | 01/01/84 |
Founder | 86 | 13/05/82 | |
Joe McNay
BRD | Director/Board Member | 90 | 01/01/02 |
Varia. 1 janv. | Capi. | |
---|---|---|
-3,15% | 89,69 Md | |
+2,50% | 41,34 Md | |
-12,59% | 33,72 Md | |
+62,74% | 26,11 Md | |
-20,74% | 14,63 Md | |
-8,82% | 12,84 Md | |
-12,34% | 11,66 Md | |
-43,92% | 11,52 Md | |
+4,27% | 8,92 Md |